Skip to main content
Q3 presentation

Philip Siberg, CEO of Senzime, presents the Q3 report for 2024.

Read Q3 report

Download presentation (PDF)

Find all presentations

CEO presentation
Safeguarding patients during anesthesia and recovery

Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally.  Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).

Regulatory PR

Interim report January – September 2024: Strong sales growth driven by accelerated sensor sales
Regulatory PR

New number of shares and votes in Senzime AB (publ)
Press release

Invitation to presentation of Senzime’s third quarter 2024 report
Financial info jan-sept 2024
Strong sales growth

Strong sales growth driven by accelerated sensor sales and increased usage of TetraGraph systems, as we continue to win more strategic hospital accounts in the US market. 

44,4

Net sales, TSEK

78

Net sales, % increase

119

Sales of disposable sensors, % increase

63.9

Gross margin excluding depreciation, %
Image

Annual Report 2023

Growth was driven by milestone new business deals and recurring sales of disposable sensors, as well as new clinical guidelines supporting Senzime’s products.

Download PDF
Reports and presentations archive
Philip Siberg

Chief Executive Officer

Subscribe

Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities. 

Contact

Get in touch with our dedicated teams.